血清CXCL12、Cav1水平对急性脑梗死患者rt-PA静脉溶栓后临床转归结局的预测价值  

Predictive value of serum CXCL12 and cav1 levels for clinical outcome of intravenous thrombolysis with rt-PA in patients with acute cerebral infarction

作　　者：李桂英 张凤莲[2] 王兴萍 Li Guiying;Zhang Fenglian;Wang Xingping(Department of Neurology,Zhengzhou Ninth People’s Hospital,Zhengzhou 450052,China;First Department of Neurology,Tangshan People’s Hospital,Tangshan 063000,China;Department of Neurology,the Fifth Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州市第九人民医院神经内科,450052 [2]唐山市人民医院神经内一科,063000 [3]郑州大学第五附属医院神经内科,450052

出　　处：《中国实用医刊》2021年第18期55-57,共3页Chinese Journal of Practical Medicine

摘　　要：目的探讨血清CXC趋化因子配体12(CXCL12)、陷窝蛋白1(Cav1)水平对急性脑梗死(ACI)患者重组组织型纤溶酶原激活物(rt-PA)静脉溶栓后临床转归结局的预测价值。方法抽取2018年1月至2020年1月郑州市第九人民医院收治的ACI患者115例,均于入院时检测血清CXCL12、Cav1水平,并实施rt-PA静脉溶栓治疗。依据治疗后患者神经功能缺损程度判定临床转归结局,115例ACI患者中结局良好51例(轻度神经功能缺损),结局不良64例(神经功能缺损重度14例、中度50例)。分析不同临床结局者血清CXCL12、Cav1水平及受试者工作曲线下面积(AUC),评估血清指标对临床结局的预测效能。结果临床结局不良者血清CXCL12、Cav1水平高于结局良好者(t=7.627、11.562,P<0.05)。ACI患者血清CXCL12、Cav1预测临床转归结局不良:AUC=0.843、0.845。结论 ACI患者行rt-PA静脉溶栓治疗后,临床转归结局尚不理想,血清CXCL12、Cav1水平与临床转归结局密切相关,可作为临床转归结局的预测因子。Objective To investigate the predictive value of serum CXC chemokine ligand 12(CXCL12)and caveolin-1(Cav1)levels for clinical outcome of intravenous thrombolysis with recombinant tissue plasminogen activator(rt-PA)in patients with acute cerebral infarction(ACI).Methods A total of 115 ACI patients admitted to the Ninth People’s Hospital of Zhengzhou from January 2018 to January 2020 were selected.Serum CXCL12 and Cav1 levels were detected at the time of admission,and rt-PA intravenous thrombolytic therapy was performed.The clinical outcome was determined based on the degree of neurological deficit after treatment.Among the 115 ACI patients,51 had good outcomes(mild neurological deficit)and 64 had poor outcomes(severe neurological deficits in 14 cases and moderate neurological deficits in 50 cases).The serum CXCL12 and Cav1 levels and the area under the receiver operating characteristic curve(AUC)of patients with different clinical outcomes were analyzed,and the predictive power of serum indexes for clinical outcomes was evaluated.Results The serum CXCL12 and Cav1 levels of patients with poor clinical outcomes were higher than those with good outcomes(t=7.627,11.562,P<0.05).Serum CXCL12 and Cav1 of ACI patients predicted poor clinical outcome:AUC=0.843,0.845.Conclusions The clinical outcome of ACI patients after rt-PA intravenous thrombolytic therapy is not ideal.The serum CXCL12 and cav1 levels are closely related to the clinical outcome,and can be used as the predictor of clinical outcome.

关 键 词：急性脑梗死 CXC趋化因子配体12 陷窝蛋白1 重组组织型纤溶酶原激活物 

分 类 号：R743.33[医药卫生—神经病学与精神病学]